Vericiguat in the management of heart failure with reduced ejection fraction-Reference-Cited by-同舟云学术

Vericiguat in the management of heart failure with reduced ejection fraction

Published:2021-05-25 Issue:4 Volume:7 Page:e65-e66
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Aziz Haya¹,Gouda Pishoy²^ORCID,Sharma Abhinav¹³^ORCID

Affiliation:

1. Division of Cardiology, Department of Medicine, McGill University Health Centre, McGill University, Montreal, QC, Canada

2. Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada

3. DREAM-CV Lab, McGill University Health Centre, McGill University, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvab022/38379714/pvab022.pdf

Reference5 articles.

1. Soluble guanylate cyclase: a potential therapeutic target for heart failure;Gheorghiade;Heart Fail Rev,2013

2. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial;Gheorghiade;JAMA,2015

3. Vericiguat in patients with heart failure and reduced ejection Fraction;Armstrong;N Engl J Med,2020

4. Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database;Hui

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany;European Journal of Clinical Pharmacology;2024-03-12

2. Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction;Scientific Reports;2022-10-05

3. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction;Journal of Pharmacy Practice;2022-03-31